What changed: Pancreatic ductal adenocarcinoma
Every dated change on the records linked to Pancreatic ductal adenocarcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
Q1 2026 · 1
2026 · 6
- 2026ApprovalDaraxonrasibDaraxonrasib approved in US
Metastatic pancreatic cancer (previously treated)
- 2026ApprovalOptune / Optune Pax (TTFields)Optune / Optune Pax (TTFields) approved in US
Locally advanced pancreatic cancer with chemotherapy
- 2026Trial resultAMPLIFY-7PAMPLIFY-7P reported
Primary DFS endpoint not met.
- 2026Trial resultRASolute 302RASolute 302 reported
OS 13.
- 2026MilestoneOptune / Optune Pax (TTFields)Optune Pax approved; daraxonrasib phase 3 enrolled
A milestone in how this cancer is treated.
- 2026MilestoneRASolute 302RASolute 302: daraxonrasib OS 13.2 vs 6.7 months (HR 0.40)
ASCO plenary and NEJM; Optune Pax approved; zoldonrasib combinations reported; AMPLIFY-7P vaccine misses.
2025 · 3
- 2025Trial resultActuate 1801 Part 3B (elraglusib)Actuate 1801 Part 3B (elraglusib) reported
Overall survival longer with elraglusib in a randomised phase 2; confirmation pending.
- 2025Trial resultPANOVA-3PANOVA-3 reported
OS 16.
- 2025MilestonePANOVA-3PANOVA-3 positive; daraxonrasib phase 1/2 OS ~14.5 months
A milestone in how this cancer is treated.
December 2024 · 1
2024 · 7
- 2024ApprovalIrinotecan (and liposomal irinotecan)Irinotecan (and liposomal irinotecan) approved in US
Liposomal irinotecan in NALIRIFOX first-line metastatic pancreatic cancer
- 2024ApprovalNALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV)NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) approved in US
First-line metastatic pancreatic adenocarcinoma
- 2024ApprovalZenocutuzumabZenocutuzumab approved in US
NRG1-fusion NSCLC and pancreatic adenocarcinoma
- 2024Trial resultAVENGER 500AVENGER 500 reported
No overall survival benefit from adding devimistat to modified FOLFIRINOX.
- 2024Trial resultLAPISLAPIS reported
Primary overall survival endpoint not met.
- 2024Trial resultPonsegromab phase 2 in cancer cachexiaPonsegromab phase 2 in cancer cachexia reported
Placebo-adjusted weight gain 2.
- 2024MilestoneNALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV)NALIRIFOX approved; zenocutuzumab for NRG1 fusions
A milestone in how this cancer is treated.
2023 · 5
- 2023Trial resultLow-dose olanzapine for cancer anorexia (Tata Memorial)Low-dose olanzapine for cancer anorexia (Tata Memorial) reported
Weight gain over 5%: 60% vs 9%; appetite improvement 43% vs 13%.
- 2023Trial resultNAPOLI 3NAPOLI 3 reported
OS HR 0.
- 2023Trial resultNOTABLE (nimotuzumab, KRAS wild-type pancreatic cancer)NOTABLE (nimotuzumab, KRAS wild-type pancreatic cancer) reported
Overall survival improved with nimotuzumab plus gemcitabine in KRAS wild-type disease.
- 2023MilestoneAutogene cevumeranAutogene cevumeran phase 1 in Nature
A milestone in how this cancer is treated.
- 2023MilestoneMRTX1133MRTX1133 regressions in G12D models; autogene cevumeran phase 1 in Nature
A milestone in how this cancer is treated.
2022 · 1
2021 · 2
December 2019 · 1
2019 · 4
- 2019ApprovalBRACAnalysis CDxBRACAnalysis CDx approved in US
Olaparib maintenance in germline BRCA-mutated metastatic pancreatic cancer
- 2019Trial resultPOLOPOLO reported
PFS HR 0.
- 2019MilestoneOlaparibPOLO: olaparib maintenance in gBRCA
A milestone in how this cancer is treated.
- 2019MilestonePOLOPOLO: olaparib maintenance in gBRCA
First biomarker-directed approval.
2018 · 2
2016 · 2
2015 · 2
- 2015ApprovalIrinotecan (and liposomal irinotecan)Irinotecan (and liposomal irinotecan) approved in US
Liposomal irinotecan with 5-FU/LV in metastatic pancreatic cancer after gemcitabine
- 2015ApprovalOptune / Optune Pax (TTFields)Optune / Optune Pax (TTFields) approved in EU
CE mark (GBM); pancreatic and NSCLC CE marks 2024-26
September 2013 · 1
2013 · 2
2011 · 3
- 2011ApprovalFOLFIRINOX / mFOLFIRINOXFOLFIRINOX / mFOLFIRINOX approved in Global
Metastatic PDAC (PRODIGE 4 / ACCORD 11; component drugs generic)
- 2011MilestonePancreatic ductal adenocarcinomaFOLFIRINOX improves survival
A milestone in how this cancer is treated.
- 2011MilestoneFOLFIRINOX / mFOLFIRINOXFOLFIRINOX: OS 11.1 vs 6.8 months
PRODIGE 4 / ACCORD 11 establishes combination chemotherapy for fit patients.